Postexposure Rabies Prophylaxis Completed in 1 Week: Preliminary Study
Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made a...
Saved in:
Published in | Clinical infectious diseases Vol. 50; no. 1; pp. 56 - 60 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
The University of Chicago Press
01.01.2010
University of Chicago Press Oxford University Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P <.001). All subjects in all groups had a NAb value ⩾0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ⩾0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions After any PEP regimen, World Health Organization recommendations require a NAb value ⩾0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. |
---|---|
AbstractList | Background
Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.
Methods
We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.
Results
Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P <.001). All subjects in all groups had a NAb value ⩾0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ⩾0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.
Conclusions
After any PEP regimen, World Health Organization recommendations require a NAb value ⩾0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. We administered the 4 ... site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2 ... site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Geometric mean titers for subjects receiving the 4 ... site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P < .001). All subjects in all groups had a NAb value ≥0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ≥0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. After any PEP regimen, World Health Organization recommendations require a NAb value ≥0.5 IU/mL on days 14 and 28. The 1 ... week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2 ... site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. (ProQuest: ... denotes formulae/symbols omitted.) Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.BACKGROUNDPatients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.METHODSWe administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.RESULTSGeometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.After any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.CONCLUSIONSAfter any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. After any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P <.001). All subjects in all groups had a NAb value ⩾0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ⩾0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions After any PEP regimen, World Health Organization recommendations require a NAb value ⩾0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. Background. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods. We administered the 4-site Intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site Intradermai injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results. Geometric mean liters for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P < .001). All subjects in all groups had a NAb value .0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value .0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions. After any PEP regimen, World Health Organization recommendations require a NAb value .=0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It Increased immunogeniclty over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. |
Author | Lohsoonthorn, Vitool Tantawichien, Terapong Wilde, Henry Ruksaket, Natthasri Kumchat, Apinya Tantawichien, Thanphet Shantavasinkul, Prapimporn Sawangvaree, Artikaya Khawplod, Pakamatz |
Author_xml | – sequence: 1 givenname: Prapimporn surname: Shantavasinkul fullname: Shantavasinkul, Prapimporn email: sprapimporn@gmail.com organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand – sequence: 2 givenname: Thanphet surname: Tantawichien fullname: Tantawichien, Thanphet organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand – sequence: 3 givenname: Henry surname: Wilde fullname: Wilde, Henry organization: Division of Research Affairs, Chulalongkorn University, Bangkok, Thailand – sequence: 4 givenname: Artikaya surname: Sawangvaree fullname: Sawangvaree, Artikaya organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand – sequence: 5 givenname: Apinya surname: Kumchat fullname: Kumchat, Apinya organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand – sequence: 6 givenname: Natthasri surname: Ruksaket fullname: Ruksaket, Natthasri organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand – sequence: 7 givenname: Vitool surname: Lohsoonthorn fullname: Lohsoonthorn, Vitool organization: Department of Preventive and Social Medicine, Chulalongkorn University, Bangkok, Thailand – sequence: 8 givenname: Pakamatz surname: Khawplod fullname: Khawplod, Pakamatz organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand – sequence: 9 givenname: Terapong surname: Tantawichien fullname: Tantawichien, Terapong organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22337852$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19995217$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0l1r1jAUB_AgE_eifgOlCuqN1bz0NIl324NzysDhC47dhDRNMM_apiYt7Pn2ZvRxg4l4lcD58eecnOyjnSEMFqHHBL8hWNRv60pSQu6hPQKMlzVIspPvGERZCSZ20X5Ka4wJERgeoF0ipQRK-B46PgtpsldjSHO0xRfdeJuKsxjGn5tOX_lUrEI_dnaybeGHghQ_rL18l4HtfO8HHTfF12luNw_Rfae7ZB9tzwP0_fj9t9VJefr5w8fV4WlpKmBTqaGhQnNBoZWubo2hDBqLW001uNyQ1JUEV0ODSescSOO4rFwrhWwqJ41mB-jVkjvG8Gu2aVK9T8Z2nR5smJPiUEFFKgb_l4zVQjDCsnx-R67DHIc8hsodyRpLIjN6ukVz09tWjdH3eXr15yUzeLEFOhnduagH49ONo5QxLoBm93JxJoaUonW3UVhdr1Itq8zw9R1o_KQnH4Ypat_9zZ8tPMzjvyOfLGadphBve-M8D4HrXC-Xur_-Ezd1HS9VzRkHdXJ-oQh8Olrxi3Ml2W86V77M |
CODEN | CIDIEL |
CitedBy_id | crossref_primary_10_1093_cid_cis389 crossref_primary_10_1371_journal_pntd_0006340 crossref_primary_10_3390_tropicalmed5010040 crossref_primary_10_1016_j_vaccine_2013_07_034 crossref_primary_10_4161_hv_26264 crossref_primary_10_1016_j_tmaid_2011_12_005 crossref_primary_10_1016_j_vaccine_2018_10_054 crossref_primary_10_1038_s41598_020_59109_w crossref_primary_10_1016_j_meegid_2014_12_024 crossref_primary_10_1007_s44197_022_00080_2 crossref_primary_10_1111_jtm_12022 crossref_primary_10_1016_j_vaccine_2011_12_028 crossref_primary_10_1111_jtm_12167 crossref_primary_10_1371_journal_pntd_0006649 crossref_primary_10_1586_14760584_2014_901893 crossref_primary_10_1586_erv_11_140 crossref_primary_10_1016_j_vaccine_2015_11_036 crossref_primary_10_1016_j_vaccine_2019_01_019 crossref_primary_10_1080_21645515_2015_1048938 crossref_primary_10_2217_fvl_15_26 crossref_primary_10_1016_j_vaccine_2018_11_010 crossref_primary_10_1038_nrdp_2017_91 crossref_primary_10_1371_journal_pntd_0004920 crossref_primary_10_1586_14760584_2014_971764 crossref_primary_10_1016_j_vaccine_2018_11_072 crossref_primary_10_1371_journal_pntd_0000982 crossref_primary_10_1016_j_vaccine_2011_03_106 crossref_primary_10_1016_j_tmaid_2015_05_008 crossref_primary_10_1080_21645515_2021_1957413 crossref_primary_10_1517_14712598_2012_691162 crossref_primary_10_3201_eid1612_100958 crossref_primary_10_1016_j_vaccine_2018_10_103 crossref_primary_10_4161_hv_20471 crossref_primary_10_1016_j_vaccine_2013_06_083 crossref_primary_10_1111_j_1708_8305_2011_00540_x crossref_primary_10_1093_jtm_tax064 crossref_primary_10_1016_j_vaccine_2019_01_041 crossref_primary_10_1016_j_antiviral_2013_07_004 crossref_primary_10_1038_nm0115_8 crossref_primary_10_1016_j_vaccine_2011_12_133 crossref_primary_10_1097_QCO_0000000000000578 crossref_primary_10_1016_j_vaccine_2021_01_023 |
ContentType | Journal Article |
Copyright | 2009 Infectious Diseases Society of America 2010 by the Infectious Diseases Society of America 2010 2015 INIST-CNRS Copyright University of Chicago, acting through its Press Jan 1, 2010 |
Copyright_xml | – notice: 2009 Infectious Diseases Society of America – notice: 2010 by the Infectious Diseases Society of America 2010 – notice: 2015 INIST-CNRS – notice: Copyright University of Chicago, acting through its Press Jan 1, 2010 |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 |
DOI | 10.1086/649211 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Virology and AIDS Abstracts MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-6591 |
EndPage | 60 |
ExternalDocumentID | 1922294001 19995217 22337852 10_1086_649211 10.1086/649211 27799506 ark_67375_HXZ_15JBC7ZX_9 |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article Feature |
GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HVGLF HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 .GJ 1KJ 3O- 70D AAPGJ AAPNW AAWDT AAYXX ABKDP ABNKS ABSMQ ABZBJ ACFRR ACPQN ACVCV ACZBC ADEYI ADMTO ADOCK AEKPW AFFQV AFSHK AFYAG AGKEF AGKRT AGMDO AHGBF AI. AIJHB AJDVS APJGH AQDSO AVNTJ BZKNY CITATION EIHJH HQ3 HTVGU J5H MBLQV OBFPC O~Y VH1 Y6R ZGI IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 |
ID | FETCH-LOGICAL-c453t-a5b28a7825d9f6dcc235be0da2a5f5219a495f65b01dff59cf794fd989b4f9ca3 |
ISSN | 1058-4838 1537-6591 |
IngestDate | Fri Jul 11 03:15:28 EDT 2025 Fri Jul 11 09:35:00 EDT 2025 Fri Jul 25 02:32:04 EDT 2025 Wed Feb 19 01:47:01 EST 2025 Mon Jul 21 09:14:49 EDT 2025 Thu Apr 24 23:00:15 EDT 2025 Tue Jul 01 01:25:44 EDT 2025 Wed Sep 11 04:51:01 EDT 2024 Thu Jun 19 15:27:37 EDT 2025 Tue Aug 05 16:50:02 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Infection Prevention Nervous system diseases Chemoprophylaxis Viral disease Rabies |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c453t-a5b28a7825d9f6dcc235be0da2a5f5219a495f65b01dff59cf794fd989b4f9ca3 |
Notes | istex:6D362E34CC637012713E3AF6EEF5EE39EF4A6947 ark:/67375/HXZ-15JBC7ZX-9 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-2 content type line 23 |
PMID | 19995217 |
PQID | 219960919 |
PQPubID | 48300 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_754541435 proquest_miscellaneous_733688313 proquest_journals_219960919 pubmed_primary_19995217 pascalfrancis_primary_22337852 crossref_primary_10_1086_649211 crossref_citationtrail_10_1086_649211 oup_primary_10_1086_649211 jstor_primary_27799506 istex_primary_ark_67375_HXZ_15JBC7ZX_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-01-01 20100101 2010-01-00 2010 2010-Jan-01 |
PublicationDateYYYYMMDD | 2010-01-01 |
PublicationDate_xml | – month: 1 year: 2010 text: 20100101 day: 1 |
PublicationDecade | 2010 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: United States |
PublicationTitle | Clinical infectious diseases |
PublicationTitleAbbrev | Clinical Infectious Diseases |
PublicationTitleAlternate | Clinical Infectious Diseases |
PublicationYear | 2010 |
Publisher | The University of Chicago Press University of Chicago Press Oxford University Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press – name: Oxford University Press |
SSID | ssj0011805 |
Score | 2.2133353 |
Snippet | Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the... Background. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing... Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the... Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of... |
SourceID | proquest pubmed pascalfrancis crossref oup jstor istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 56 |
SubjectTerms | Adult Analysis of Variance Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Viral - blood ARTICLES AND COMMENTARIES Biological and medical sciences Cercopithecus aethiops Clinical medicine Disease prevention Female Geometric mean Horses Human viral diseases Humans Immune system Immunization, Passive - methods Immunoglobulins Immunoglobulins - administration & dosage Infectious diseases Injections, Intradermal Male Medical research Medical sciences Middle Aged Neutralizing antibodies Nonprofit organizations Post exposure prophylaxis Post-Exposure Prophylaxis - methods Prospective Studies Rabies Rabies - immunology Rabies - prevention & control Rabies vaccines Rabies Vaccines - administration & dosage Rabies Vaccines - adverse effects Rabies Vaccines - immunology Vaccination Vaccines Vero Cells Viral diseases Viral diseases of the nervous system |
Title | Postexposure Rabies Prophylaxis Completed in 1 Week: Preliminary Study |
URI | https://api.istex.fr/ark:/67375/HXZ-15JBC7ZX-9/fulltext.pdf https://www.jstor.org/stable/27799506 https://www.ncbi.nlm.nih.gov/pubmed/19995217 https://www.proquest.com/docview/219960919 https://www.proquest.com/docview/733688313 https://www.proquest.com/docview/754541435 |
Volume | 50 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWMBCgKFEW3tEraVIe2l0CFNkriUXXU2ll8iO3YyEUgKRE1YiiGF8Dp13dISrLcNOlyEQyR1sI3Gs6Qb2YQ-iA86mPuhhaLSGiBSc0txiLfskMiRG7bOWUyGvm8F3SG_skYj1utJmtptWSf-Y_fxpX8D6pwDnCVUbL_gGx9UTgBvwFfOALCcPwrjGWl3Xw9u5GrfEcXlIHXK5n_MHJTup4s1McOuOQyv9KRozLzSs7FVFXymt8qEuHWtm67ipOsOFqrRbWFU9ve_U7cG8SXcb_bOx2eKSt0TmcTmeFqQ-qVXUbddqeb9DQNiRaz75tY61H37DjRs16x4SH341Hc-3YZXySqLYYXvqa3tLkwUZJTHwh1bGhZG6tVzKiphnX-2S1x0zoVB43ZWRcfuKP3bbUNFfjELVX3VmLtXya8moYIppEXRhhm8F0XvAyp14-7p_UmlBMpBmz9tI3SVPpOW7bMrvws1xWttYqXfDKjC4BN6Cop97sxypwZPENPSz_EjLVQPUetvHiBHp2XTIuXKGnKlqlly2zIllnLljkpTMeUsmU2ZMtUsvUKDb8mg3bHKktuWNzH3tKimLkRBasRZ0QEGeeuh1luZ9SlWIClRyg41CLAzHYyITDhAvS5yEhEmC8Ip94e2iluivwNMqnIGKO-LRjnfhhIXeBHPMwJBRvcZqGBPlaDl_IyH70sizJNFS8iClI9yAZ6X_eb6Qwsd3p8UmNfN9P5teQrhjjtjK9SB598aYdX45QYaE-BU3cE1AnBdmCgfUDr3ssfboG4-XcpPgY6qFBNS-2wSF1J7wdjHG5q1q2guuV-HC1y-H5TmYk0ijzHe6ALODi-dGkM9FqLy-YhwbUDRML9Pz3eAXqsKS9y3fAt2lnOV_k7sKSX7FDJ-08grMl5 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Postexposure+Rabies+Prophylaxis+Completed+in+1+Week+Preliminary+Study&rft.jtitle=Clinical+infectious+diseases&rft.au=SHANTAVASINKUL%2C+Prapimporn&rft.au=TANTAWICHIEN%2C+Thanphet&rft.au=WILDE%2C+Henry&rft.au=SAWANGVAREE%2C+Artikaya&rft.date=2010&rft.pub=Oxford+University+Press&rft.issn=1058-4838&rft.volume=50&rft.issue=1&rft.spage=56&rft.epage=60&rft_id=info:doi/10.1086%2F649211&rft.externalDBID=n%2Fa&rft.externalDocID=22337852 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |